CY1107550T1 - Συνδυαστικα εμβολια μηνιγγιτιδας b/c - Google Patents

Συνδυαστικα εμβολια μηνιγγιτιδας b/c

Info

Publication number
CY1107550T1
CY1107550T1 CY20071100128T CY071100128T CY1107550T1 CY 1107550 T1 CY1107550 T1 CY 1107550T1 CY 20071100128 T CY20071100128 T CY 20071100128T CY 071100128 T CY071100128 T CY 071100128T CY 1107550 T1 CY1107550 T1 CY 1107550T1
Authority
CY
Cyprus
Prior art keywords
bingual
vaccines
cognitive
serogroup
oligosaccharides
Prior art date
Application number
CY20071100128T
Other languages
Greek (el)
English (en)
Inventor
Dan M Granoff
Ingeborg S Aaberge
Bjorn Haneberg
Johan Holst
Howard Raff
Original Assignee
Novartis Vaccines And Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics, Inc. filed Critical Novartis Vaccines And Diagnostics, Inc.
Publication of CY1107550T1 publication Critical patent/CY1107550T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20071100128T 1998-05-29 2007-01-31 Συνδυαστικα εμβολια μηνιγγιτιδας b/c CY1107550T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8735198P 1998-05-29 1998-05-29
US10644698P 1998-10-30 1998-10-30
EP99926046A EP1079857B1 (en) 1998-05-29 1999-05-28 Combination meningitidis b/c vaccines

Publications (1)

Publication Number Publication Date
CY1107550T1 true CY1107550T1 (el) 2013-03-13

Family

ID=26776879

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100128T CY1107550T1 (el) 1998-05-29 2007-01-31 Συνδυαστικα εμβολια μηνιγγιτιδας b/c

Country Status (14)

Country Link
US (1) US8007815B1 (enExample)
EP (2) EP1079857B1 (enExample)
JP (2) JP5074644B2 (enExample)
AT (1) ATE346609T1 (enExample)
AU (2) AU761495B2 (enExample)
BR (1) BR9910749A (enExample)
CA (1) CA2332963C (enExample)
CY (1) CY1107550T1 (enExample)
DE (1) DE69934225T2 (enExample)
DK (1) DK1079857T3 (enExample)
ES (2) ES2278446T3 (enExample)
NZ (1) NZ508771A (enExample)
PT (2) PT1079857E (enExample)
WO (1) WO1999061053A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ES2588917T3 (es) * 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
ES2615362T3 (es) 2001-07-27 2017-06-06 Glaxosmithkline Biologicals Sa Adhesinas de meningococos
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
HRP20120433T1 (en) * 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
WO2011024072A2 (en) * 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR112015005056A2 (pt) * 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
AU640118B2 (en) * 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
DK0710118T3 (da) 1994-04-20 1999-08-09 Us Army Vaccine mod infektioner med gram-negative bakterier
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
PT854729E (pt) * 1995-09-18 2004-08-31 Us Army Med Res Mat Com Usamrm Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente
DE19601754A1 (de) * 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) * 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
DE69708318T3 (de) * 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
EP0994723A1 (en) * 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
JP2001510169A (ja) * 1997-07-17 2001-07-31 ノース アメリカン ワクチン， インコーポレイテッド Ｂ型髄膜炎菌性ポーリンおよびＨ．ｉｎｆｌｕｅｎｚａｅ多糖体を含む免疫原性結合体
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos

Also Published As

Publication number Publication date
DE69934225D1 (de) 2007-01-11
US8007815B1 (en) 2011-08-30
BR9910749A (pt) 2001-02-13
ES2485940T3 (es) 2014-08-14
CA2332963A1 (en) 1999-12-02
AU4221599A (en) 1999-12-13
ATE346609T1 (de) 2006-12-15
EP2796148A3 (en) 2015-02-25
EP1079857A1 (en) 2001-03-07
EP1079857B1 (en) 2006-11-29
WO1999061053A1 (en) 1999-12-02
CA2332963C (en) 2013-07-23
NZ508771A (en) 2003-08-29
EP2796148A2 (en) 2014-10-29
HK1034460A1 (en) 2001-10-26
ES2278446T3 (es) 2007-08-01
JP2009292851A (ja) 2009-12-17
AU2003244518A1 (en) 2003-09-25
PT1079857E (pt) 2007-02-28
JP2002516292A (ja) 2002-06-04
JP5074644B2 (ja) 2012-11-14
DE69934225T2 (de) 2007-09-27
PT1741443E (pt) 2014-07-31
AU761495B2 (en) 2003-06-05
DK1079857T3 (da) 2007-01-29

Similar Documents

Publication Publication Date Title
DK1079857T3 (da) Meningitidis B/C-kombinationsvacciner
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
DE60032250D1 (de) Behandlung von Allergien
EE200100645A (et) Amüloidogeense haiguse preventsioon ja ravi
DE60210456D1 (de) Solubisierung von kapseln polysacchariden
DE60111209D1 (de) Endoventrikuläre vorrichtung zur behandlung und korrektur der kardiomyopathie
ATE325620T1 (de) Streptococcus pneumoniae proteine und impfstoffe
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
DK1265577T3 (da) Medicinsk eller dentalmedicinsk behandlingsstol
HUP9801266A2 (hu) Multimer, rekombináns ureázvakcina
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
IS1910B (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
EP1741443A3 (en) Combination meningitidis B/C vaccines
ATE334697T1 (de) Boviner atmungs- und darmcoronavirus als impfstoff
CY1106092T1 (el) Χρηση του μακρου μοριου της πεντραξινης ρτχ3 για τη θepαπεια ασθενειων που προκαλουνται απο μια μεταβαλλομενη ενepγοποιηση του αυξητικου παραγοντα fgf-2
ITTO20020284A1 (it) Procedimento per la sterilizzazione e la neutralizzazione di odori dell'aria.
DK0894500T3 (da) Streptococcus equi-vaccine
EP2364726A3 (en) Vaccine against neisseria infection
MY124071A (en) Treatment of viral disease in swine
ITMI913493A1 (it) Dispositivo per la disinfezione o la immunizzazione di zone del corpo umano esposte al contagio, da germi, batteri e virus
SE9701026D0 (sv) use of avian antibodies
BG101145A (bg) Използване на /s/-аденозил-l-метионин /саме/ i неговите физиологично съвместими соли за лечение нареперфузионно увреждане, причинено от временна фокална исхемиа
FI953622L (fi) Ifenprodiilin ja sen diastereoisomeerien käyttö lääkeaineiden valmistukseen, jotka lääkeaineet ovat käyttökelpoisia perifeeristen neuropatiatilojen ja keskushermoston degeneratiivisten sairauksien hoitoon